A Tetrameric Biotin-Avidin Scaffold Using Anti-CD19 (FMC63) Traptavidin Fusion Enables High-Avidity CAR-T Cells for...

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Chimeric antigen receptor-T cell (CAR-T) therapy is a promising treatment for hematologic malignancies.
• Current CAR-T therapies face limitations in CAR-T cell activation and overall efficacy.

Purpose of the Study:

• To develop a novel tetramer CAR-T (tCAR-T) system to enhance CAR-T cell activation and antitumor activity.
• To evaluate the efficacy of the tCAR-T system against CD19-expressing hematologic malignancies.

Main Methods:

• Engineered T cells with a tetrameric antibody scaffold targeting CD19, incorporating specific signaling domains.
• Assembled the tCAR-T system using biotin-avidin interaction to enhance binding avidity.
• Tested tCAR-T cell cytotoxicity against CD19+ B-cell lymphoblast cell lines (Raji, Nalm-6, Ramos).

Main Results:

• The tCAR-T system demonstrated significantly enhanced antibody avidity and antigen engagement.
• tCAR-T exhibited potent cytotoxicity against CD19+ B-cell lymphoblast lines.
• tCAR-T showed superior antitumor activity, enhanced cytokine release, and improved target cell elimination compared to Kymriah.

Conclusions:

• The tetrameric arrangement of CAR-T cells enhances binding avidity, leading to improved cancer treatment efficacy.
• The tCAR-T system overcomes limitations of conventional CAR-T therapy, showing potential for better therapeutic outcomes.
• This innovative approach offers modular targeting flexibility for improved hematologic malignancy treatment.